Table 2.
Seizure reduction (≥ /< 50%) and related factors
| Entire epilepsy group (n = 45) | Other indications group (n = 17) | Epilepsy indication group (n = 28) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| ≥ 50% seizure reduction n/N( %) | < 50% seizure reduction n/N( %) | ≥ 50% seizure reduction n/N( %) | < 50% seizure reduction n/N( %) | ≥ 50% seizure reduction n/N(%) | < 50% seizure reduction n/N (%) | ||||
| All | 14/45 (31) | 30/45 (69)* | 5/17 (29) | 12/17 (71) | 9/28 (32) | 19/28 (68)* | |||
| Norway | 4/26 (15) | 22/26 (85) | 1/7 (14) | 6/7 (86) | 3/19 (16) | 16/19 (84) | |||
| Denmark | 10/19 (53) | 9/19 (47) | 4/9 (44) | 6/9 (66) | 6/9 (67) | 3/9 (33) | |||
| ≥ 3 seizure types before treatment | Yes | 4/10 (40) | 6/10 (60) | 4/13 (39) | 9/13 (31) | 3/6 (50) | 3/6 (50) | ||
| No | 10/35 (29) | 25/35 (71) | 1/4 (25) | 3/4 (75) | 6/22 (27) | 16/22 (73) | |||
| GTK before treatment | Yes | 6/22 (27) | 16/22 (73) | 3/10 (30) | 7/10 (70) | 3/12 (25) | 9/12 (75) | ||
| No | 8/23 (65) | 15/23 (65) | 2/7 (29) | 5/7 (71) | 6/16 (37.5) | 10/16 (62.5) | |||
| ≥ 3 ASMs at start of treatment | Yes | 6/20 (30) | 14/20 (70) | 3/6 (50) | 3/6 (50) | 6/14 (42) | 8/14 (58) | ||
| No | 8/25 (32) | 17/25 (68) | 2/11 (18) | 9/11 (82) | 3/14 (21) | 11/14 (79) | |||
| Median weekly seizure** | < 7 | 5/15 (33) | 10/15 (67) | < 1.5 | 1/5 (20) | 4/5 (80) | < 28 | 4/8 (50) | 9/18/(50) |
| Frequency before treatment | ≥ 7 | 9/26 (35) | 17/26 (65) | ≥ 1.5 | 3/9 (33) | 6/9 (67) | ≥ 28 | 4/8 (50) | 9/18/(50) |
| Age at start of treatment | < 18 | 11/24 (46) | 13/24 (54)* | 2/3 (67) | 1/3 (33) | 9/21 (43) | 12/21 (57) | ||
| ≥ 18 | 3/21 (14) | 18/21 (86) | 3/14 (21) | 11/14 (79) | 0/7 (0) | 7/7 (100) | |||
| Major change in ASMs | No | 7/26 (27) | 19/26 (73) | 3/10 (30) | 7/10 (70) | 4/16 (25) | 12/16 (75) | ||
| Yes | 7/19 (37) | 12/19 (63) | 2/7 (29) | 5/7 (71) | 5/12 (42) | 7/12 (58) | |||
*Significant difference